Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial Post author: Post published:December 10, 2024 Post category:uncategorized Post comments:0 Comments A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). You Might Also Like Study tracks long COVID’s shifting course in general population February 7, 2024 Optical coherence tomography reveals age-specific plaque vulnerabilities in STEMI patients January 29, 2024 Study reveals impact of socioeconomic status on children’s anxiety in research settings March 3, 2024 Leave a Reply Cancel replyYou must be logged in to post a comment.
Optical coherence tomography reveals age-specific plaque vulnerabilities in STEMI patients January 29, 2024
Study reveals impact of socioeconomic status on children’s anxiety in research settings March 3, 2024